Kaj Blennow (Former)
41 – 50 of 230
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
(
- Contribution to journal › Article
- 2022
-
Mark
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau
(
- Contribution to journal › Article
-
Mark
Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest
(
- Contribution to journal › Article
-
Mark
Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings
(
- Contribution to journal › Article
-
Mark
Dynamics of Selected Biomarkers in Cerebrospinal Fluid During Complex Endovascular Aortic Repair – A Pilot Study
(
- Contribution to journal › Article
-
Mark
Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk
(
- Contribution to journal › Article
-
Mark
The accuracy and robustness of plasma biomarker models for amyloid PET positivity
(
- Contribution to journal › Article
-
Mark
Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients
(
- Contribution to journal › Article
-
Mark
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
(
- Contribution to journal › Article
-
Mark
Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology
(
- Contribution to journal › Article